Side Effects of Drugs Annual
A Worldwide Yearly Survey of New Data and Trends in Adverse Drug Reactions
- 1st Edition, Volume 29 - June 28, 2007
- Editor: Jeffrey K. Aronson
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 4 - 5 1 9 8 6 - 3
- eBook ISBN:9 7 8 - 0 - 0 8 - 0 5 2 2 8 1 - 4
The Side Effects of Drugs Annual was first published in 1977. It has been continually published since then, as a yearly update to the voluminous encyclopedia Meyler's Side Effe… Read more
The Side Effects of Drugs Annual was first published in 1977. It has been continually published since then, as a yearly update to the voluminous encyclopedia Meyler's Side Effects of Drugs. Each new Annual continues to provide clinicians and medical investigators with a reliable and critical yearly survey of new data and trends in the area of Adverse Drug Reactions and Interactions. An international team of specialists has contributed to the Annuals by selecting critically from each year's writing all that is truly new and informative, by critically interpreting it, and by pointing to whatever is misleading.
- Provides a critical yearly survey of new data and trends
- Includes an essay that describes the modern approach to classifying adverse drug reactions
- Special reviews in this Annual include, among other topics: Antipsychotic drugs and now-onset diabetes mellitus, Treating asthma during pregnancy, and MMR vaccine and autism
Pharmacologists, clinicians, pharmaceutical companies, clinical toxicologists, Clinical pharmacologists, and medical libraries
Contributors
Special reviews
Cumulative index of special reviews, Annuals 14–28
Table of Essays, Annuals 1–28
DoTS classification of adverse drug reactions
How to use this book
Data mining in drug safety
1 Central nervous system stimulants and drugs that suppress appetite
Methylxanthines (SEDA-26, 1; SEDA-27, 1; SEDA-28, 1)
Amphetamines (SED-15, 180; SEDA-26, 30; SEDA-27, 29; SEDA-28, 4, 28)
Drugs that suppress appetite (SEDA-26, 6; SEDA-27, 4; SEDA-28, 6)
Drugs used in Alzheimer's disease (SEDA-26, 7; SEDA-27, 7; SEDA-28, 9)
2 Antidepressant drugs
Mania as an adverse effect of antidepressants
Monoamine oxidase inhibitors (SED-15, 2371; SEDA-24, 12)
Tricyclic antidepressants (SED-15, 3489; SEDA-26, 11; SEDA-27, 11; SEDA-28, 15)
Selective serotonin re-uptake inhibitors (SSRIs) (SED-15, 3109; SEDA-26, 11; SEDA-27, 12; SEDA-28, 15)
Serotonin and noradrenaline re-uptake inhibitors (SNRIs)
Other antidepressants
3 Lithium
4 Drugs of abuse
Cannabinoids (SED-15, 614; SEDA-26, 36; SEDA-27, 32; SEDA-28, 36)
Cocaine (SED-15, 848; SEDA-26, 27; SEDA-27, 33; SEDA-28, 38; see also Chapter 11)
Opioid analgesics (SED-15, 2619; SEDA-27, 38; SEDA-28, 44)
5 Hypnosedatives and anxiolytics
Azaspirones (SEDA-26, 49; SEDA-27, 43; SEDA-28, 52)
Benzodiazepines (SED-15, 429; SEDA-26, 46; SEDA-27, 43; SEDA-28, 52)
Other hypnotics and sedatives
6 Antipsychotic drugs
General (SED-15, 2438)
Individual drugs
7 Antiepileptic drugs
8 Opioid analgesics and narcotic antagonists
Opioid receptor agonists
Partial opioid receptor agonists
Opioid receptor antagonists
Miscellaneous compounds
9 Anti-inflammatory and antipyretic analgesics and drugs used in gout
Coxibs and cardiovascular disease
Individual drugs and classes
Arylalkanoic acid derivatives (SED-15, 2555; SEDA-26, 115; SEDA-27, 115; SEDA-28, 126)
Oxicams (SEDA-15, 2555; SEDA-27, 116; SEDA-28, 128)
Drugs used in the treatment of gout
10 General anesthetics and therapeutic gases
Sedation in special circumstances
Anesthetic vapors (SED-15, 1489; SEDA-26, 132; SEDA-27, 119; SEDA-28, 139)
Nitrous oxide (SED-15, 2550; SEDA-27, 120; SEDA-28, 140)
Xenon (SED-15, 3693; SEDA-27, 120; SEDA-28, 140)
Intravenous agents. Miscellaneous non-barbiturate anesthetics
11 Local anesthetics
General topics (SED-15, 2116)
Effects related to modes of use (SED-15, 2121)
Individual compounds
12 Neuromuscular blocking agents and skeletal muscle relaxants
Anaphylaxis due to neuromuscular blocking agents
Skeletal muscle relaxants (SEDA-26, 152; SEDA-27, 141; SEDA-28, 157)
13 Drugs that affect autonomic functions or the extrapyramidal system
Drugs that stimulate both alpha- and beta-adrenoceptors (SEDA-26, 156; SEDA-27, 145; SEDA-28, 160)
Drugs that predominantly stimulate alpha1-adrenoceptors (SEDA-26, 157; SEDA-27, 147; SEDA-28, 161)
Drugs that stimulate beta1-adrenoceptors (SEDA-26, 159; SEDA-27, 147)
Drugs that stimulate dopamine receptors (SEDA-26, 159; SEDA-27, 148; SEDA-28, 162)
Other drugs that increase dopamine activity (SEDA-26, 162; SEDA-27, 151; SEDA-28, 164)
Drugs that affect the cholinergic system (SEDA-26, 164; SEDA-27, 152; SEDA-28, 165)
14 Dermatological drugs, topical agents, and cosmetics
Contact allergens
Photochemotherapy (SED-15, 2823; SEDA-28, 171)
Vitamin A (Retinoids) (SED-15, 3653; SEDA-27, 159; SEDA-28, 171; for vitamin A carotenoids see Chapter 34)
15 Antihistamines (H1 receptor antagonists)
16 Drugs acting on the respiratory tract
Inhaled glucocorticoids (SED-15, 958; SEDA-26, 186; SEDA-27, 174; SEDA-28, 184)
Beta2-adrenoceptor agonists (SED-15, 448; SEDA-26, 190; SEDA-27, 179; SEDA-28, 188)
Anticholinergic drugs (SED-15, 264; SEDA-26, 194; SEDA-27, 180; SEDA-28, 190)
Leukotriene modifiers (SED-15, 2025; SEDA-26, 193; SEDA-27, 177; SEDA-28, 191)
Combinations of drugs
17 Positive inotropic drugs and drugs used in dysrhythmias
Cardiac glycosides (SED-15, 648; SEDA-26, 198; SEDA-27, 185; SEDA-28, 196)
Other positive inotropic drugs (SED-15, 2822; SEDA-26, 201; SEDA-27, 188; SEDA-28, 199)
Drugs used in dysrhythmias
18 Beta-adrenoceptor antagonists and antianginal drugs
Beta-adrenoceptor antagonists (SED-15, 452; SEDA-26, 223; SEDA-27, 203; SEDA-28, 217)
Nitrates, organic (SED-15, 2529; SEDA-26, 224; SEDA-27, 204; SEDA-28, 218)
Calcium channel blockers (SED-15, 598; SEDA-26, 225; SEDA-27, 224; SEDA-28, 218)
19 Drugs acting on the cerebral and peripheral circulations
Drugs used in the treatment of arterial disorders of the brain and limbs
Drugs used in the treatment of venous disorders
Drugs used in the treatment of migraine
Other peripheral vasodilators
20 Antihypertensive drugs
Moving targets and patterns of prescribing
Angiotensin converting enzyme inhibitors (SED-15, 226; SEDA-26, 234; SEDA-27, 213; SEDA-28, 227)
Angiotensin II receptor antagonists (SED-15, 223; SEDA-26, 236; SEDA-27, 214; SEDA-28, 229)
Endothelin receptor antagonists (SED-15, 1215; SEDA-26, 233; SEDA-27, 214)
Drugs that act on the sympathetic nervous system (SEDA-27, 216; SEDA-28, 230)
Imidazoline receptor antagonists
Direct vasodilators
21 Diuretics
Hyponatremia and loop and thiazide diuretics
Urinary tract
Carbonic anhydrase inhibitors (SED-15, 643; SEDA-26, 238; SEDA-27, 220; SEDA-28, 233)
Thiazide diuretics (SED-15, 3375; SEDA-26, 239; SEDA-27, 220; SEDA-28, 233)
Loop diuretics (SED-15, 567, 1454; SEDA-26, 239; SEDA-27, 220; SEDA-28, 233)
Aldosterone receptor antagonists
Osmotic diuretics
22 Metals
23 Metal antagonists
Iron chelators
Penicillamine and related drugs
Polystyrene sulfonates (SED-15, 2894; SEDA-26, 256; SEDA-27, 236; SEDA-28, 259)
24 Antiseptic drugs and disinfectants
Bisbiguanides
Iodophors (SEDA-15, 1896; SEDA-27, 240; SEDA-28, 262)
25 Penicillins, cephalosporins, other beta-lactam antibiotics, and tetracyclines
Antimicrobial drug resistance: a serious adverse effect exemplified by avoparcin and vancomycin-resistant enterococci
Beta-lactam antibiotics (SED-15, 478; SEDA-26, 279; SEDA-27, 242; SEDA-28, 267)
Carbapenems (SED-15, 638; SEDA-26, 265; SEDA-27, 246)
Cephalosporins (SED-15, 688; SEDA-26, 264; SEDA-27, 245; SEDA-28, 268)
Monobactams (SED-15, 2378; SEDA-27, 247)
Penicillins (SED-15, 2756; SEDA-26, 262; SEDA-27, 244)
Tetracyclines (SED-15, 3330; SEDA-26, 265; SEDA-27, 247; SEDA-28, 270)
Glycylcyclines
26 Miscellaneous antibacterial drugs
Aminoglycoside antibiotics (SED-15, 118; SEDA-26, 271; SEDA-27, 251; SEDA-28, 274)
Chloramphenicol and related drugs (SED-15, 706; SEDA-26, 273; SEDA-26, 274; SEDA-26, 276)
Fluoroquinolones (SED-15, 1396; SEDA-26, 274; SEDA-27, 254; SEDA-28, 276)
Fusidic acid (SED-15, 1460; SEDA-26, 281; SEDA-27, 259; SEDA-28, 280)
Glycopeptides (SEDA-26, 281; SEDA-27, 259; SEDA-28, 280)
Ketolides (SED-15, 1976; SEDA-26, 283; SEDA-27, 260; SEDA-28, 281)
Lincosamides (SED-15, 2063; SEDA-26, 283; SEDA-27, 260; SEDA-28, 281)
Macrolide antibiotics (SED-15, 2183; SEDA-26, 284; SEDA-27, 261; SEDA-28, 282)
Nitrofurantoin (SED-15, 2542; SEDA-26, 288; SEDA-27, 264; SEDA-28, 284)
Oxazolidinones (SED-15, 2645; SEDA-26, 288; SEDA-27, 264; SEDA-28, 284)
Polymyxins (SED-15, 2891; SEDA-26, 289; SEDA-27, 265; SEDA-28, 285)
Streptogramins (SED-15, 3182; SEDA-26, 289; SEDA-27, 265; SEDA-28, 285)
Sulfonamides, trimethoprim, and co-trimoxazole (SED-15, 3216, 3510; SEDA-26, 290; SEDA-27, 266; SEDA-28, 285)
Other antimicrobial drugs
27 Antifungal drugs
Allylamines (SEDA-26, 309; SEDA-27, 284; SEDA-28, 294)
Amphotericin (SED-15, 192; SEDA-26, 302; SEDA-27, 276; SEDA-28, 295)
Antifungal azoles (SED-15, 301; SEDA-26, 304; SEDA-27, 278; SEDA-28, 299)
Echinocandins (SED-15, 1197; SEDA-26, 311; SEDA-28, 309)
28 Antiprotozoal drugs
Antimalarial drugs
4-Aminoquinolines (chloroquine and congeners) (SEDA-26, 315; SEDA-27, 289; SEDA-28, 315)
Pyrimethamine and combinations (SED-15, 2984; SEDA-26, 320; SEDA-27, 293; SEDA-28, 318)
Quinine and congeners (SED-15, 3002; SEDA-26, 318; SEDA-27, 290)
Endoperoxides
Drugs used in the treatment of pneumocystis jiroveci infections (SEDA-26, 320; SEDA-27, 295; SEDA-28, 322)
29 Antiviral drugs
Drugs active against cytomegalovirus
Drugs active against herpesviruses (SEDA-26, 329; SEDA-27, 305; SEDA-28, 328)
Drugs active against hepatitis viruses
Drugs active against human immunodeficiency virus: nucleoside analogue reverse transcriptase inhibitors (NRTI) (SED-15, 2586; SEDA-26, 330; SEDA-27, 306; SEDA-28, 332)
Drugs active against human immunodeficiency virus: nucleotide analogue reverse transcriptase inhibitors
Drugs active against human immunodeficiency virus: non-nucleoside reverse transcriptase inhibitors (NNRTI) (SED-15, 2553; SEDA-27, 308; SEDA-28, 334)
Drugs active against human immunodeficiency virus: protease inhibitors (SED-15, 2965; SEDA-26, 332; SEDA-28, 335)
Drugs active against human immunodeficiency virus: inhibitors of HIV fusion
Drugs active against influenza viruses: neuraminidase inhibitors (SED-15, 2436; SEDA-26, 334; SEDA-27, 317; SEDA-28, 337)
30 Drugs used in tuberculosis and leprosy
Immune reconstitution disease
31 Antihelminthic drugs
Artemisinin derivatives (SED-15, 342; SEDA-26, 319; SEDA-27, 292; SEDA-28, 320)
Benzimidazoles (SED-15, 424; SEDA-25, 367; SEDA-26, 344; SEDA-27, 326)
32 Vaccines
Bacterial vaccines
Viral vaccines
33 Blood, blood components, plasma, and plasma products
Albumin (SED-15, 54; SEDA-28, 371)
Anticoagulant proteins (SED-15, 266; SEDA-28, 371)
Blood transfusion (SED-15, 529; SEDA-28, 369)
Blood substitutes (SEDA-28, 370)
Plasma products (SED-15, 2847)
Plasma substitutes (SEDA-26, 374; SEDA-27, 353; SEDA-28, 371)
Globulins
Coagulation proteins (SED-15, 845; SEDA-28, 375)
Erythropoietin and derivatives (SED-15, 1243)
Stem cells
34 Formulations used in nutrition
Parenteral nutrition (SED-15, 2700; SEDA-26, 377; SEDA-27, 355; SEDA-28, 383)
Vitamins of the B group (SEDA-26, 419; SEDA-27, 407; SEDA-28, 387)
Vitamin D Analogues (SED-15, 3669; SEDA-28, 388)
Vitamin E (SED-15, 3677)
35 Drugs affecting blood coagulation, fibrinolysis, and hemostasis
Coumarin anticoagulants (SED-15, 983; SEDA-26, 379; SEDA-27, 358; SEDA-28, 391)
Heparins (SED-15, 1590; SEDA-26, 379; SEDA-27, 358; SEDA-28, 391)
Thrombolytic agents (SED-15, 3402; SEDA-28, 392)
Short polysaccharide inhibitors of coagulating factors (SEDA-27, 359; SEDA-28, 392)
Direct thrombin inhibitors (SED-15, 1142; SEDA-27, 359)
Drugs that alter platelet function (SEDA-25, 412; SEDA-26, 380; SEDA-27, 360; SEDA-28, 396)
Hemostatic agents
36 Gastrointestinal drugs
Antiemetics and drugs that affect gastrointestinal motility
5-HT3 receptor antagonists (SED-15, 1365; SEDA-26, 382; SEDA-27, 363; SEDA-28, 402)
Histamine H2 receptor antagonists (SED-15, 1629; SEDA-26, 384; SEDA-27, 363; SEDA-28, 403)
Proton pump inhibitors (SED-15, 2973; SEDA-26, 384; SEDA-27, 364; SEDA-28, 403)
Antidiarrheal agents (SEDA-27, 367; SEDA-28, 406)
Laxatives and oral bowel preparations (SED-15, 2008; SEDA-26, 387; SEDA-27, 367; SEDA-28, 406)
Aminosalicylates (SED-15, 138; SEDA-26, 387; SEDA-27, 367; SEDA-28, 408)
Bile acids (SED-15, 515; SEDA-26, 389; SEDA-27, 369; SEDA-28, 409)
Prebiotics
Other gastrointestinal agents
37 Drugs that act on the immune system: cytokines and monoclonal antibodies
Colony-stimulating factors (SEDA-26, 398; SEDA-27, 391; SEDA-28, 415)
Interferons (SED-15, 1841; SEDA-26, 393; SEDA-27, 383; SEDA-28, 416)
Interleukins (SED-15, 1842; SEDA-26, 397; SEDA-27, 390; SEDA-28, 424)
Tumor necrosis factor (TNF) antagonists (SEDA-26, 399; SEDA-27, 393; SEDA-28, 425)
Monoclonal antibodies (SED-15, 2380; SEDA-26, 402; SEDA-27, 378; SEDA-28, 434)
38 Drugs that act on the immune system: immunosuppressive and immunostimulatory drugs
Immunosuppressive drugs
Immunoenhancing drugs
Other drugs
39 Corticotrophins, corticosteroids, and prostaglandins
Systemic glucocorticoids (SED-15, 906; SEDA-26, 427; SEDA-27, 414; SEDA-28, 471)
Nasal glucocorticoids
Intra-articular glucocorticoids
Prostaglandins and analogues (SED-15, 2955; SEDA-26, 430; SEDA-27, 417; SEDA-28, 476)
40 Sex hormones and related compounds, including hormonal contraceptives
Gonadotropins and ovulation-inducing drugs (SED-15, 1536; SEDA-26, 434; SEDA-27, 420; SEDA-28, 480)
Estrogens (SED-15, 1253; SEDA-26, 436; SEDA-27, 422; SEDA-28, 481)
Hormonal contraceptives (SED-15, 1642 et seq; SEDA-26, 442; SEDA-27, 426; SEDA-28, 487)
Antiestrogens and selective estrogen receptor modulators (SERMs) (SEDA-26, 445; SEDA-27, 429; SEDA-28, 490)
Progestogens (SED-15, 2930; SEDA-26, 447; SEDA-27, 433; SEDA-28, 493)
Progesterone antagonists (SEDA-26, 448; SEDA-27, 433; SEDA-28, 494)
Anabolic steroids, androgens, and related compounds (SED-15, 216; SEDA-26, 449; SEDA-27, 434; SEDA-28, 495)
Antiandrogens (SEDA-26, 451; SEDA-27, 435; SEDA-28, 497)
Miscellaneous compounds
41 Thyroid hormones and antithyroid drugs
THYROID HORMONES (SED-15, 3409; SEDA-26, 45; SEDA-27, 442; SEDA-28, 505)
Antithyroid drugs (SED-15, 3387; SEDA-26, 458; SEDA-27, 442; SEDA -28, 506)
42 Insulin, other hypoglycemic drugs, and glucagon
Insulin (SED-15, 1761; SEDA-26, 461; SEDA-27, 446; SEDA-28, 509)
New ultrashort-acting insulins (SEDA-26, 463; SEDA-27, 449; SEDA-28, 512)
Long-acting insulins (SEDA-26, 463; SEDA-27, 450; SEDA-28, 513)
Alpha glucosidase inhibitors (SED-15, 85; SEDA-26, 466; SEDA-27, 452; SEDA-28, 514)
Amylin analogues (SEDA-27, 453; SEDA-28, 514)
Biguanides (SED-15, 506; SEDA-26, 467; SEDA-27, 453; SEDA-28, 514)
Meglitinides (SED-15, 2238; SEDA-26, 468; SEDA-27, 455; SEDA-28, 518)
Sulfonylureas (SED-15, 3230; SEDA-26, 469; SEDA-27, 456; SEDA-28, 518)
Thiazolidinediones (glitazones) (SED-15, 3380; SEDA-26, 471; SEDA-27, 457; SEDA-28, 519)
Combinations of oral hypoglycemic drugs
43 Miscellaneous hormones
Somatostatin (growth hormone release-inhibiting hormone) and analogues (SED-15, 3160; SEDA-26, 480; SEDA-27, 467; SEDA-28, 530)
Vasopressin and analogues (SED-15, 3609; SEDA-26, 482; SEDA-27, 469; SEDA-28, 531)
44 Drugs that affect lipid metabolism
45 Cytostatic drugs
General
46 Radiological contrast agents
Types of contrast agents
MRI contrast media
47 Drugs used in ocular treatment
Intravitreal and parabulbar injection of drugs
Ocular dyes
48 Treatments used in complementary and alternative medicine
Herbal medicines (SED-15, 1609; SEDA-26, 528; SEDA-27, 512; SEDA-28, 573)
Non-herbal supplements
Acupuncture (SED-15, 890; SEDA-26, 535; SEDA-27, 520; SEDA-28, 581)
Colonic irrigation
Homeopathy (SED-15, 892; SEDA-28, 582)
Spinal manipulation (SED-15, 893; SEDA-26, 536; SEDA-27, 521; SEDA-28, 582)
49 Miscellaneous drugs and materials, medical devices, and techniques
Dyestuffs
Medical devices
49 Miscellaneous drugs and materials, medical devices, and techniques
Address list of national centres that participate in the WHO Drug Monitoring Programme
Index of drugs
Index of adverse effects
- Edition: 1
- Volume: 29
- Published: June 28, 2007
- Language: English
JA
Jeffrey K. Aronson
Dr Jeffrey K. Aronson is a consultant clinical pharmacologist and physician in the Department of Primary Health Care in the University of Oxford and a consultant physician in the Oxford Radcliffe Hospitals Trust. He has been associated with the Meyler series since 1977 and has published many research papers on adverse drug reactions. He is President of the British Pharmacological Society and serves on many committees concerned with drug therapy, including the Technology Appraisal Committee of the UK’s National Institute for Health and Clinical Excellence (NICE) and the Joint Formulary Committees of the British National Formulary and the British National Formulary for Children.
Affiliations and expertise
consultant clinical pharmacologist and physician in the Department of Primary Health Care in the University of Oxford and a consultant physician in the Oxford Radcliffe Hospitals TrustRead Side Effects of Drugs Annual on ScienceDirect